Cinfa shows biosimilar equivalenceCinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers … more ➔
An X-ray look at GPCR structureUKs Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find … more ➔
Partnership targets leukaemiaNordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody. more ➔
Biotech responds to Brexit voteAfter the British people voted in favour of leaving the European Union, the industry is grappling with the profound impact this will likely have on the economy, research and politics. Representatives … more ➔
Malin hauls in €70m from EIBUK investment vehicle Malin has secured another €70m to invest in innovation and research across the European life sciences. The European Investment Bank will provide a debt facility over a period … more ➔
TxCell licenses CAR-T techTxCell has jumped on its option for a licensing agreement with the Weizmann Institute of Sciences tech transfer arm after it was granted a far-reaching patent for redirected, genetically engineered … more ➔
Cat allergy setback for CircassiaCircassia suffered a severe blow when its cat allergy immunotherapy failed to outcompete the placebo in a Phase III trial. The companys shares, listed in London, plunged to a third of its previous … more ➔
Across the blood-brain barrier with ultras...CarTheras ultrasound device opens a gate for therapeutic molecules into the brain, study shows. more ➔
Novartis to develop new antimalarialWith support from the Medicines for Malaria Venture and Gates Foundation, Novartis will tackle resistant malaria with a new compound. more ➔
Gilde closes €250m growth fundEuropean specialist investment firm Gilde Healthcare has closed its €250m fund for later stage and growth capital in medtech, digital health and therapeutics. The oversubscribed fund will invest in … more ➔
